Neha Sangal
Ophthalmology · Tulsa, OKNPI 1508000977
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 44.8% of the total.
Across 191 payments — averaging $28.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$781
- NEW World Medical,inc.$390
- Ocular Therapeutix, Inc.$327
- Johnson & Johnson Surgical Vision, Inc.$247
- Glaukos Corporation$239
- plus $1K from 7 others
What the payments were for
- Food & beverage$5,456100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $2,459 |
| Alcon | 31 | $781 |
| NEW World Medical,inc. | 5 | $390 |
| Ocular Therapeutix, Inc. | 8 | $327 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $247 |
| Glaukos Corporation | 2 | $239 |
| Sun Pharmaceutical Industries Inc. | 5 | $201 |
| Bausch & Lomb Americas Inc. | 11 | $186 |
| Tarsus Pharmaceuticals, Inc. | 6 | $158 |
| Sight Sciences, Inc. | 7 | $149 |
| Rxsight Inc | 2 | $138 |
| Aerie Pharmaceuticals, Inc. | 1 | $118 |
| Novartis | 5 | $90 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$379
- XEN GLAUCOMA TREATMENT SYSTEM$259
- Kahook Dual Blade$187
- Streamline Surgical System$187
- Ahmed Glaucoma Valve$187
- DEXTENZA$150
- iDose$136
- CEQUA$128
- XELPROS$128
- RXSIGHT INJECTOR HANDPIECE$124
- RXSIGHT CONTACT LENS$124
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$124
- RXSIGHT INJECTOR CARTRIDGE$124
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$124
- Rhopressa$118
- Rocklatan$118
- LUMIGAN$117
- DURYSTA$117
- Tecnis Simplicity$102
How this compares
$5,483 in reported general payments places this provider in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 163 | $87,133 |
| RocklatanNetarsudil Mesylat/Latanoprost | 75 | $51,464 |
| RhopressaNetarsudil Mesylate | 95 | $47,321 |
| CombiganBrimonidine Tartrate/Timolol | 70 | $32,469 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 59 | $18,578 |
| Alphagan PBrimonidine Tartrate | 37 | $13,673 |
| Prednisolone Acetate | 261 | $12,627 |
| VyzultaLatanoprostene Bunod | 28 | $12,240 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 54 | $9,201 |
| Latanoprost | 637 | $8,896 |
| RestasisCyclosporine | 12 | $8,623 |
| Travoprost | 43 | $7,552 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 434 | $6,424 |
| Ketorolac Tromethamine | 289 | $6,378 |
| Brimonidine Tartrate | 342 | $4,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $2,459 | $141,898282 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $118 | $98,785170 claims |
| AlconSimbrinza | $781 | $18,57859 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $186 | $12,24028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Tulsa
- Shehzad BatliwalaTulsa$11K
- Thomas FinleyTulsa$9K
- Jamal SiddiquiTulsa$7K
- Kelli DyerTulsa$6K
- Lars FreisbergTulsa$6K
- Thomas BriggsTulsa$4K
- Marc GoldbergTulsa$4K
- Daniel LangleyTulsa$3K
- Mark AllisonTulsa$3K
- Justin ParschauerTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.